View More View Less
  • 1 Debreceni Egyetem, Orvos- és Egészségtudományi Centrum Anyagcsere-betegségek Tanszék, I. Belgyógyászati Klinika Debrecen Nagyerdei krt. 98. 4032
  • | 2 Békés Megyei Képviselő-testület Pándy Kálmán Kórháza II. Belgyógyászat-Kardiológia Gyula
Restricted access

A korábbi epidemiológiai tanulmányok eredményei azt igazolták, hogy a HDL-koleszterin a cardiovascularis megbetegedések önálló rizikófaktora, plazmaszintjének emelése a cardiovascularis prevenció egyik fontos eleme. A HDL-nek a reverz koleszterintranszportban betöltött központi szerepe mellett egyéb kedvező biológiai, az érelmeszesedés elleni védőhatása is van. Ezek közé tartozik az antioxidáns, az antiinflammatorikus, az antitrombotikus/profibrinolitikus és a vazoprotektív hatás. A jelenlegi ajánlások az agresszív életmódváltást, a niacin, a fibrátok, a statinok vagy ezek kombinációját javasolják a HDL-koleszterin-szint emelésére. Emellett számos új, a HDL-re épülő terápiás eljárás tesztelése történt meg az utóbbi években, illetve van folyamatban. Idetartoznak a nikotinsav-származékok új formái, illetve receptoragonistái, a CETP-inhibitorok, a kannabinoid-1-receptor-antagonisták, a PPAR-agonisták, az LXR/FXR receptoragonisták és az apoA1- és/vagy foszfolipidterápia. Jelen közleményünkben áttekintjük a korábbi klinikai tanulmányokat, epidemiológiai megfigyeléseket, alapkutatásokat, illetve a legfontosabb új terápiás eljárásokkal végzett klinikai vizsgálatok eredményeit.

  • Castelli, W. P.: Cholesterol and lipids in the risk of coronary artery disease – the Framingham Heart Study. Can. J. Cardiol., 1988, 4 (Suppl A) , 5A–10A.

    Castelli W. P. , 'Cholesterol and lipids in the risk of coronary artery disease – the Framingham Heart Study ' (1988 ) 4 Can. J. Cardiol. : 5A -10A.

    • Search Google Scholar
  • Brown, G., Albers, J. J., Fisher, L. D. és mtsai: Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N. Engl. J. Med., 1990, 323 , 1289–1298.

    Fisher L. D. , 'Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B ' (1990 ) 323 N. Engl. J. Med. : 1289 -1298.

    • Search Google Scholar
  • Gordon, D. J., Probstfield, J. L., Garrison, R. J. és mtsai: High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation, 1989, 79 , 8–15.

    Garrison R. J. , 'High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies ' (1989 ) 79 Circulation : 8 -15.

    • Search Google Scholar
  • von Eckardstein, A., Assmann, G.: Prevention of coronary heart disease by raising high-density lipoprotein cholesterol? Curr. Opin. Lipidol., 2000, 11 , 627–637.

    Assmann G. , 'Prevention of coronary heart disease by raising high-density lipoprotein cholesterol? ' (2000 ) 11 Curr. Opin. Lipidol. : 627 -637.

    • Search Google Scholar
  • Rader, D. J.: Molecular regulation of HDL metabolism and function: implications for novel therapies. J. Clin. Invest., 2006, 116 , 3090–3100.

    Rader D. J. , 'Molecular regulation of HDL metabolism and function: implications for novel therapies ' (2006 ) 116 J. Clin. Invest. : 3090 -3100.

    • Search Google Scholar
  • Hessler, J. R., Robertson, A. L., Jr., Chisolm, G. M.: LDL-induced cytotoxicity and its inhibition by HDL in human vascular smooth muscle and endothelial cells in culture. Atherosclerosis, 1979, 32 , 213–229.

    Chisolm G. M. , 'LDL-induced cytotoxicity and its inhibition by HDL in human vascular smooth muscle and endothelial cells in culture ' (1979 ) 32 Atherosclerosis : 213 -229.

    • Search Google Scholar
  • Navab, M., Imes, S. S., Hama, S. Y. és mtsai: Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J. Clin. Invest., 1991, 88 , 2039–2046.

    Hama S. Y. , 'Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein ' (1991 ) 88 J. Clin. Invest. : 2039 -2046.

    • Search Google Scholar
  • Wilson, P. W., Abbott, R. D., Castelli, W. P.: High density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis, 1988, 8 , 737–741.

    Castelli W. P. , 'High density lipoprotein cholesterol and mortality. The Framingham Heart Study ' (1988 ) 8 Arteriosclerosis : 737 -741.

    • Search Google Scholar
  • Mackness, M. I., Durrington, P. N., Mackness, B.: How high-density lipoprotein protects against the effects of lipid peroxidation. Curr. Opin. Lipidol., 2000, 11 , 383–388.

    Mackness B. , 'How high-density lipoprotein protects against the effects of lipid peroxidation ' (2000 ) 11 Curr. Opin. Lipidol. : 383 -388.

    • Search Google Scholar
  • Lusis, A. J.: Atherosclerosis. Nature, 2000, 407 , 233–241.

    Lusis A. J. , 'Atherosclerosis ' (2000 ) 407 Nature : 233 -241.

  • Fleisher, L. N., Tall, A. R., Witte, L. D. és mtsai: Stimulation of arterial endothelial cell prostacyclin synthesis by high density lipoproteins. J. Biol. Chem., 1982, 257 , 6653–6655.

    Witte L. D. , 'Stimulation of arterial endothelial cell prostacyclin synthesis by high density lipoproteins ' (1982 ) 257 J. Biol. Chem. : 6653 -6655.

    • Search Google Scholar
  • Zeiher, A. M., Schachlinger, V., Hohnloser, S. H. és mtsai: Coronary atherosclerotic wall thickening and vascular reactivity in humans. Elevated high-density lipoprotein levels ameliorate abnormal vasoconstriction in early atherosclerosis. Circulation, 1994, 89 , 2525–2532.

    Hohnloser S. H. , 'Coronary atherosclerotic wall thickening and vascular reactivity in humans. Elevated high-density lipoprotein levels ameliorate abnormal vasoconstriction in early atherosclerosis ' (1994 ) 89 Circulation : 2525 -2532.

    • Search Google Scholar
  • Nofer, J. R., Walter, M., Kehrel, B. és mtsai: HDL3-mediated inhibition of thrombin-induced platelet aggregation and fibrinogen binding occurs via decreased production of phosphoinositide-derived second messengers 1,2-diacylglycerol and inositol 1,4,5-tris-phosphate. Arterioscler. Thromb. Vasc. Biol., 1998, 18 , 861–869.

    Kehrel B. , 'HDL3-mediated inhibition of thrombin-induced platelet aggregation and fibrinogen binding occurs via decreased production of phosphoinositide-derived second messengers 1,2-diacylglycerol and inositol 1,4,5-tris-phosphate ' (1998 ) 18 Arterioscler. Thromb. Vasc. Biol. : 861 -869.

    • Search Google Scholar
  • Lerch, P. G., Spycher, M. O., Doran, J. E.: Reconstituted high density lipoprotein (rHDL) modulates platelet activity in vitro and ex vivo. Thromb. Haemost., 1998, 80 , 316–320.

    Doran J. E. , 'Reconstituted high density lipoprotein (rHDL) modulates platelet activity in vitro and ex vivo ' (1998 ) 80 Thromb. Haemost. : 316 -320.

    • Search Google Scholar
  • Ansell, B. J., Fonarow, G. C., Fogelman, A. M.: The paradox of dysfunctional high-density lipoprotein. Curr. Opin. Lipidol., 2007, 18 , 427–434.

    Fogelman A. M. , 'The paradox of dysfunctional high-density lipoprotein ' (2007 ) 18 Curr. Opin. Lipidol. : 427 -434.

    • Search Google Scholar
  • Hovingh, G. K., de Groot, E., van der Steeg, W. és mtsai: Inherited disorders of HDL metabolism and atherosclerosis. Curr. Opin. Lipidol., 2005, 16 , 139–145.

    Steeg W. , 'Inherited disorders of HDL metabolism and atherosclerosis ' (2005 ) 16 Curr. Opin. Lipidol. : 139 -145.

    • Search Google Scholar
  • Davignon, J., Dufour, R.: Primary hyperlipidemias: an atlas of investigation and diagnosis. Oxford, Clinical Publishing, 2007.

    Dufour R. , '', in Primary hyperlipidemias: an atlas of investigation and diagnosis , (2007 ) -.

  • Belalcazar, L. M., Ballantyne, C. M.: Defining specific goals of therapy in treating dyslipidemia in the patient with low high-density lipoprotein cholesterol. Progr. Cardiovasc. Dis., 1998, 41 , 151–174.

    Ballantyne C. M. , 'Defining specific goals of therapy in treating dyslipidemia in the patient with low high-density lipoprotein cholesterol ' (1998 ) 41 Progr. Cardiovasc. Dis. : 151 -174.

    • Search Google Scholar
  • Rubins, H. B., Robins, S. J., Collins, D. és mtsai: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N. Engl. J. Med., 1999, 341 , 410–418.

    Collins D. , 'Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group ' (1999 ) 341 N. Engl. J. Med. : 410 -418.

    • Search Google Scholar
  • Ericsson, C. G., Hamsten, A., Nilsson, J. és mtsai: Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet, 1996, 347 , 849–853.

    Nilsson J. , 'Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients ' (1996 ) 347 Lancet : 849 -853.

    • Search Google Scholar
  • The BIP Study Group: Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation, 2000, 102, 1 , 21–27.

    'Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study ' (2000 ) 102 Circulation : 21 -27.

    • Search Google Scholar
  • Tanne, D., Koren-Morag, N., Graff, E. és mtsai: Blood lipids and first-ever ischemic stroke/transient ischemic attack in the Bezafibrate Infarction Prevention (BIP) Registry: high triglycerides constitute an independent risk factor. Circulation, 2001, 104 , 2892–2897.

    Graff E. , 'Blood lipids and first-ever ischemic stroke/transient ischemic attack in the Bezafibrate Infarction Prevention (BIP) Registry: high triglycerides constitute an independent risk factor ' (2001 ) 104 Circulation : 2892 -2897.

    • Search Google Scholar
  • Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: The Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet, 2001, 357, 905–910.

  • Staels, B., Dallongeville, J., Auwerx, J. és mtsai: Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation, 1998, 98 , 2088–2093.

    Auwerx J. , 'Mechanism of action of fibrates on lipid and lipoprotein metabolism ' (1998 ) 98 Circulation : 2088 -2093.

    • Search Google Scholar
  • Lavie, C. J., Mailander, L., Milani, R. V.: Marked benefit with sustained-release niacin therapy in patients with „isolated” very low levels of high-density lipoprotein cholesterol and coronary artery disease. Am. J. Cardiol., 1992, 69 , 1083–1085.

    Milani R. V. , 'Marked benefit with sustained-release niacin therapy in patients with „isolated” very low levels of high-density lipoprotein cholesterol and coronary artery disease ' (1992 ) 69 Am. J. Cardiol. : 1083 -1085.

    • Search Google Scholar
  • Alderman, J. D., Pasternak, R. C., Sacks, F. M. és mtsai: Effect of a modified, well-tolerated niacin regimen on serum total cholesterol, high density lipoprotein cholesterol and the cholesterol to high density lipoprotein ratio. Am. J. Cardiol., 1989, 64 , 725–729.

    Sacks F. M. , 'Effect of a modified, well-tolerated niacin regimen on serum total cholesterol, high density lipoprotein cholesterol and the cholesterol to high density lipoprotein ratio ' (1989 ) 64 Am. J. Cardiol. : 725 -729.

    • Search Google Scholar
  • Luria, M.: Effect of low-dose niacin on high-density lipoprotein cholesterol and total cholesterol/high-density lipoprotein cholesterol ratio. Arch. Intern. Med., 1988, 148 , 2493–2495.

    Luria M. , 'Effect of low-dose niacin on high-density lipoprotein cholesterol and total cholesterol/high-density lipoprotein cholesterol ratio ' (1988 ) 148 Arch. Intern. Med. : 2493 -2495.

    • Search Google Scholar
  • Brown, B. G., Canner, P. L., McGovern, M. és mtsai: Nicotinic acid. In: Clinical Lipidology: A Companion to Braunwald’s Heart Disease. Szerk.: Ballantyne, C. M., Philadelphia, Elsevier, 2008 (in press).

  • Knopp, R. H., Alagona, P., Davidson, M. és mtsai: Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism, 1998, 47 , 1097–1104.

    Davidson M. , 'Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia ' (1998 ) 47 Metabolism : 1097 -1104.

    • Search Google Scholar
  • Jin, F. Y., Kamanna, V. S., Kashyap, M. L.: Niacin accelerates intracellular ApoB degradation by inhibiting triacylglycerol synthesis in human hepatoblastoma (HepG2) cells. Arterioscler. Thromb. Vasc. Biol., 1999, 19 , 1051–1059.

    Kashyap M. L. , 'Niacin accelerates intracellular ApoB degradation by inhibiting triacylglycerol synthesis in human hepatoblastoma (HepG2) cells ' (1999 ) 19 Arterioscler. Thromb. Vasc. Biol. : 1051 -1059.

    • Search Google Scholar
  • Jin, F. Y., Kamanna, V. S., Kashyap, M. L.: Niacin decreases removal of high-density lipoprotein apolipoprotein A-I, but not cholesterol ester by Hep G2 cells. Implication for reverse cholesterol transport. Arterioscler. Thromb. Vasc. Biol., 1997, 17 , 2020–2028.

    Kashyap M. L. , 'Niacin decreases removal of high-density lipoprotein apolipoprotein A-I, but not cholesterol ester by Hep G2 cells. Implication for reverse cholesterol transport ' (1997 ) 17 Arterioscler. Thromb. Vasc. Biol. : 2020 -2028.

    • Search Google Scholar
  • Pike, N. B.: Flushing out the role of GPR109A (HM74A) in the clinical efficacy of nicotinic acid. J. Clin. Invest., 2005, 115 , 3400–3403.

    Pike N. B. , 'Flushing out the role of GPR109A (HM74A) in the clinical efficacy of nicotinic acid ' (2005 ) 115 J. Clin. Invest. : 3400 -3403.

    • Search Google Scholar
  • Scandinavian Simvastatin Survival Study Group: Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet, 1995, 345 , 1274–1275.

    'Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S) ' (1995 ) 345 Lancet : 1274 -1275.

    • Search Google Scholar
  • Ballantyne, C. M., Herd, J. A., Ferlic, L. L. és mtsai: Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy. Circulation, 1999, 99 , 736–743.

    Ferlic L. L. , 'Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy ' (1999 ) 99 Circulation : 736 -743.

    • Search Google Scholar
  • Shepherd, J., Cobbe, S. M., Ford, I. és mtsai: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med., 1995, 333 , 1301–1307.

    Ford I. , 'Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group ' (1995 ) 333 N. Engl. J. Med. : 1301 -1307.

    • Search Google Scholar
  • Downs, J. R., Clearfield, M., Weis, S. és mtsai: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA, 1998, 279 , 1615–1622.

    Weis S. , 'Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study ' (1998 ) 279 JAMA : 1615 -1622.

    • Search Google Scholar
  • The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med., 1998, 339 , 1349–1357.

    'Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels ' (1998 ) 339 N. Engl. J. Med. : 1349 -1357.

    • Search Google Scholar
  • Ballantyne, C. M., Herd, J. A., Ferlic, L. L. és mtsai: Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy. Circulation, 1999, 99 , 736–743.

    Ferlic L. L. , 'Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy ' (1999 ) 99 Circulation : 736 -743.

    • Search Google Scholar
  • Sacks, F. M., Pfeffer, M. A., Moye, L. A. és mtsai: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N. Engl. J. Med., 1996, 335 , 1001–1009.

    Moye L. A. , 'The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators ' (1996 ) 335 N. Engl. J. Med. : 1001 -1009.

    • Search Google Scholar
  • Schaefer, J. R., Schweer, H., Ikewaki, K. és mtsai: Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease. Atherosclerosis, 1999, 144 , 177–184.

    Ikewaki K. , 'Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease ' (1999 ) 144 Atherosclerosis : 177 -184.

    • Search Google Scholar
  • Sviridov, D., Nestel, P., Watts, G.: Statins and metabolism of high density lipoprotein. Cardiovasc. Hematol. Agents Med. Chem., 2007, 5 , 215–221.

    Watts G. , 'Statins and metabolism of high density lipoprotein ' (2007 ) 5 Cardiovasc. Hematol. Agents Med. Chem. : 215 -221.

    • Search Google Scholar
  • Guyton, J. R., Goldberg, A. C., Kreisberg, R. A. és mtsai: Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. Am. J. Cardiol., 1998, 82 , 737–743.

    Kreisberg R. A. , 'Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia ' (1998 ) 82 Am. J. Cardiol. : 737 -743.

    • Search Google Scholar
  • Jacobson, T. A., Chin, M. M., Fromell, G. J. és mtsai: Fluvastatin with and without niacin for hypercholesterolemia. Am. J. Cardiol., 1994, 74 , 149–154.

    Fromell G. J. , 'Fluvastatin with and without niacin for hypercholesterolemia ' (1994 ) 74 Am. J. Cardiol. : 149 -154.

    • Search Google Scholar
  • Wierzbicki, A. S., Lumb, P. J., Cheung, J. és mtsai: Fenofibrate plus simvastatin therapy versus simvastatin plus cholestyramine therapy for familial hypercholesterolaemia. QJM, 1997, 90 , 631–634.

    Cheung J. , 'Fenofibrate plus simvastatin therapy versus simvastatin plus cholestyramine therapy for familial hypercholesterolaemia ' (1997 ) 90 QJM : 631 -634.

    • Search Google Scholar
  • Wiklund, O., Angelin, B., Bergman, M. és mtsai: Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. Am. J. Med., 1993, 94 , 13–20.

    Bergman M. , 'Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia ' (1993 ) 94 Am. J. Med. : 13 -20.

    • Search Google Scholar
  • Ellen, R. L., McPherson, R.: Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia. Am. J. Cardiol., 1998, 81 , 60B–65B.

    McPherson R. , 'Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia ' (1998 ) 81 Am. J. Cardiol. : 60B -65B.

    • Search Google Scholar
  • Brown, B. G., Zhao, X. Q., Chait, A. és mtsai: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N. Engl. J. Med., 2001, 345 , 1583–1592.

    Chait A. , 'Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease ' (2001 ) 345 N. Engl. J. Med. : 1583 -1592.

    • Search Google Scholar
  • Pi-Sunyer, F. X., Aronne, L. J., Heshmati, H. M. és mtsai: Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA, 2006, 295 , 761–775.

    Heshmati H. M. , 'Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial ' (2006 ) 295 JAMA : 761 -775.

    • Search Google Scholar
  • Calabresi, L., Sirtori, C. R., Paoletti, R. és mtsai: Recombinant apolipoprotein A-I Milano for the treatment of cardiovascular diseases. Curr. Atheroscler. Rep., 2006, 8 , 163–167.

    Paoletti R. , 'Recombinant apolipoprotein A-IMilano for the treatment of cardiovascular diseases ' (2006 ) 8 Curr. Atheroscler. Rep. : 163 -167.

    • Search Google Scholar
  • Navab, M., Anantharamaiah, G. M., Reddy, S. T. és mtsai: Apolipoprotein A-I mimetic peptides and their role in atherosclerosis prevention. Nat. Clin. Pract. Cardiovasc. Med., 2006, 3 , 540–547.

    Reddy S. T. , 'Apolipoprotein A-I mimetic peptides and their role in atherosclerosis prevention ' (2006 ) 3 Nat. Clin. Pract. Cardiovasc. Med. : 540 -547.

    • Search Google Scholar
  • Wong, N. C.: Novel therapies to increase apolipoprotein AI and HDL for the treatment of atherosclerosis. Curr. Opin. Investig. Drugs, 2007, 8 , 718–728.

    Wong N. C. , 'Novel therapies to increase apolipoprotein AI and HDL for the treatment of atherosclerosis ' (2007 ) 8 Curr. Opin. Investig. Drugs : 718 -728.

    • Search Google Scholar
  • Knight, B. L., Patel, D. D., Humphreys, S. M. és mtsai: Inhibition of cholesterol absorption associated with a PPAR alpha-dependent increase in ABC binding cassette transporter A1 in mice. J. Lipid. Res., 2003, 44 , 2049–2058.

    Humphreys S. M. , 'Inhibition of cholesterol absorption associated with a PPAR alpha-dependent increase in ABC binding cassette transporter A1 in mice ' (2003 ) 44 J. Lipid. Res. : 2049 -2058.

    • Search Google Scholar
  • van Eck, M., Pennings, M., Hoekstra, M. és mtsai: Scavenger receptor BI and ATP-binding cassette transporter A1 in reverse cholesterol transport and atherosclerosis. Curr. Opin. Lipidol., 2005, 16 , 307–315.

    Hoekstra M. , 'Scavenger receptor BI and ATP-binding cassette transporter A1 in reverse cholesterol transport and atherosclerosis ' (2005 ) 16 Curr. Opin. Lipidol. : 307 -315.

    • Search Google Scholar
  • Fruchart, J. C., Duriez, P.: Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism. Drugs Today (Barc.), 2006, 42 , 39–64.

    Duriez P. , 'Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism ' (2006 ) 42 Drugs Today (Barc.) : 39 -64.

    • Search Google Scholar
  • Rittershaus, C. W., Miller, D. P., Thomas, L. J.: Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler. Thromb. Vasc. Biol., 2000, 20 , 2106–2112.

    Thomas L. J. , 'Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis ' (2000 ) 20 Arterioscler. Thromb. Vasc. Biol. : 2106 -2112.

    • Search Google Scholar
  • Nissen, S. E., Tardif, J. C., Nicholls, S. J. és mtsai: Effect of torcetrapib on the progression of coronary atherosclerosis. N. Engl. J. Med., 2007, 356 , 1304–1316.

    Nicholls S. J. , 'Effect of torcetrapib on the progression of coronary atherosclerosis ' (2007 ) 356 N. Engl. J. Med. : 1304 -1316.

    • Search Google Scholar
  • Kastelein, J. J., van Leuven, S. I., Burgess, L. és mtsai: Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N. Engl. J. Med., 2007, 356 , 1620–1630.

    Burgess L. , 'Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia ' (2007 ) 356 N. Engl. J. Med. : 1620 -1630.

    • Search Google Scholar
  • Bots, M. L., Visseren, F. L., Evans, G. W. és mtsai: Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet, 2007, 370 , 153–160.

    Evans G. W. , 'Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial ' (2007 ) 370 Lancet : 153 -160.

    • Search Google Scholar
  • Barter, P. J., Caulfield, M., Eriksson, M. és mtsai: Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med., 2007, 357 , 2109–2122.

    Eriksson M. , 'Effects of torcetrapib in patients at high risk for coronary events ' (2007 ) 357 N. Engl. J. Med. : 2109 -2122.

    • Search Google Scholar
  • The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial: Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA, 1995, 273 , 199–208.

    'Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women ' (1995 ) 273 JAMA : 199 -208.

    • Search Google Scholar
  • Burgess, J. W., Neville, T. A., Rouillard, P.: Phosphatidylinositol increases HDL-C levels in humans. J. Lipid. Res., 2005, 46 , 350–355.

    Rouillard P. , 'Phosphatidylinositol increases HDL-C levels in humans ' (2005 ) 46 J. Lipid. Res. : 350 -355.

    • Search Google Scholar

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Jan 2021 11 0 1
Feb 2021 5 0 0
Mar 2021 13 1 1
Apr 2021 11 1 1
May 2021 9 0 0
Jun 2021 9 0 0
Jul 2021 0 0 0